https://www.bioworld.com/rss en-us Brightgene Bio-Medical Technology Co. Ltd. has patented new calcitonin receptor (CALCR; CT-R) and amylin AMY3 receptor agonists potentially useful for the treatment of obesity and metabolic disorders. http://www.bioworld.com/articles/732390 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732390-brightgene-bio-medical-discovers-new-calcitonin-amy3-receptor-agonists FAM3D is a protein mainly expressed in the gastrointestinal tract, but also detectable in vascular endothelial cells. It is known to worsen intestinal inflammation by recruiting neutrophils, but its role in atherosclerosis is not well understood. http://www.bioworld.com/articles/732378 Fri, 03 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732378-targeting-fam3d-as-a-strategy-against-atherosclerosis Human heart within crosshairs Ribocure Pharmaceuticals AB, a subsidiary of Suzhou Ribo Life Science Co. Ltd., and Madrigal Pharmaceuticals Inc. have achieved the first drug candidate nomination within their siRNA partnership. http://www.bioworld.com/articles/732357 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732357-ribocure-and-madrigal-nominate-sirna-drug-candidate-for-mash Illustration of RNA strands being delivered by nanoparticles Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). http://www.bioworld.com/articles/732393 Wed, 01 Jul 2026 08:00:00 -0400 https://www.bioworld.com/articles/732393-hk-biotech-listings-gain-traction-in-q2-with-trio-of-june-ipos HKEX on phone, digital stock chart Credit: piter2121 - stock.adobe.com Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results. http://www.bioworld.com/articles/732349 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732349-corxel-vincentages-oral-glp-1-meets-phase-ii-obesity-endpoints Glass of water and tablets The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. http://www.bioworld.com/articles/732354 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732354-cinp-2026-gut-microbiota-could-predict-antidepressant-response Illustration demonstrating gut-brain axis Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone (GH), does not contain GH sequence and selectively activates human GHR for the treatment of GH deficiency (GHD). It is designed to enable once-every-4-week dosing. http://www.bioworld.com/articles/732314 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732314-gensci-134-a-long-acting-growth-hormone-receptor-agonist-fusion-protein 3D illustration of human growth hormone molecules Human growth hormone. Genescience Pharmaceuticals Co. Ltd. has been developing an SLC6A19 inhibitor – Gensci-144 – for the potential treatment of chronic kidney disease (CKD). http://www.bioworld.com/articles/732211 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732211-gensci-144-shows-renoprotection-in-ckd Illustration of diseased kidney The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. http://www.bioworld.com/articles/732204 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732204-cinp-2026-gut-microbiota-could-predict-antidepressant-response Illustration demonstrating gut-brain axis Graves’ disease is a form of autoimmune hyperthyroidism where the main extrathyroidal feature is thyroid eye disease. Autoantibodies that stimulate thyroid-stimulating hormone receptor (TSHR) are released and orchestrate hormone production in the thyroid tissue and the orbit. Regeneron Pharmaceuticals Inc. has developed REGN-24493, a monoclonal antibody (MAb) that binds TSHR and blocks its activation by those autoantibodies. http://www.bioworld.com/articles/732191 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732191-regeneron-reports-tshr-blocking-mab-for-graves-disease Thyroid anatomy Hypoparathyroidism is a rare disorder characterized by low levels of parathyroid hormone (PTH) that lead to low blood calcium levels and hyperphosphatemia. Septerna Inc. is developing a small-molecule PTH1 receptor (PTH1R) agonist, SEP-479, designed to replace PTH and normalize serum calcium. http://www.bioworld.com/articles/732190 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732190-septerna-obtains-promising-preclinical-results-with-sep-479-for-hypoparathyroidism Photo of pipette with test tube Mwyngil Therapeutics Inc. has released promising in vivo proof-of-concept results from its GPR75 inverse agonist program, supporting the potential of GPR75 modulation as a differentiated therapeutic approach for obesity and cardiometabolic disease. http://www.bioworld.com/articles/732188 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732188-mwyngils-gpr75-inverse-agonists-show-promise-for-obesity Obesity and heart disease illustration Cholesterol is essential for cell function, but its balance hinges on hepatic LDL receptor (LDLR) abundance, which dictates how efficiently the liver clears circulating lipoproteins. Researchers at the University of California, San Diego (UCSD) identified a Ral-dependent pathway by which elevated cholesterol intake reduces hepatic LDLR availability, pointing to a potential target for lipid-lowering therapies. http://www.bioworld.com/articles/732186 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732186-cholesterol-rewrites-the-rules-of-ldl-clearance LDL particle binding to the LDL receptor LDL particle binding to the LDL receptor. Ascletis Pharma Inc. has received IND clearance from the FDA for ASC-35, a once-monthly subcutaneously administered GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual peptide agonist, for the treatment of obesity. http://www.bioworld.com/articles/732131 Thu, 25 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732131-fda-clears-ind-for-ascletis-pharmas-asc-35-for-obesity Eli Lilly and Co. posted $19.8 billion in first-quarter 2026 revenue, driven by tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The Indianapolis-based drugmaker is channeling cash flow from these blockbuster GLP-1 drugs into an aggressive dealmaking campaign — about $25.1 billion across 10 announced acquisitions so far this year and more than $26 billion in other closed deals. http://www.bioworld.com/articles/732076 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732076-lillys-glp-1-windfall-fuels-m-and-a-land-grab-across-10-deals-25b Business handshake and holographic dollar sign Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according to top-line results. http://www.bioworld.com/articles/732050 Wed, 24 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732050-corxel-vincentages-oral-glp-1-meets-phase-ii-obesity-endpoints Glass of water and tablets Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. is seeking up to HK$1.22 billion (US$155 million) in a Hong Kong IPO to advance its lead phase III chronic kidney disease candidate, MT-1013, and next-generation obesity therapies. http://www.bioworld.com/articles/732154 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732154-chinas-micot-targets-hk12b-ipo-to-advance-metabolic-portfolio IPO, coins, upward arrow The industry is stepping up its campaign to persuade European governments to increase their drugs budgets, in what is described as a landmark report making the case that spending on patented drugs is not a cost to be contained, but an investment in health and the economy. http://www.bioworld.com/articles/732066 Tue, 23 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732066-efpia-report-every-1-spent-on-new-drugs-returns-567-to-europes-economy Pill with Euro currency symbol Zydus Lifesciences Ltd. has synthesized co-crystals of saroglitazar and chitosan acting as triglyceride-lowering agents found to be potentially useful for the treatment of dyslipidemia and hyperglycemia. http://www.bioworld.com/articles/732124 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732124-zydus-lifesciences-discloses-new-triglyceride-lowering-agents Lu-AG-22515, also known as velaprumig, is a recombinant fusion protein that targets CD40 ligand (CD40L) and human serum albumin (HSA), thereby blocking the binding between CD40 and CD40L, a known signaling pathway involved in several autoimmune diseases. Researchers at H. Lundbeck A/S evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) profile of Lu-AG-22515 in cynomolgus monkeys, as well as the impact of its inhibitory effect in the preclinical setting of thyroid eye disease (TED). http://www.bioworld.com/articles/732119 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732119-lundbecks-lu-ag-22515-shows-promise-in-thyroid-eye-disease Close up of eye and vision test Acromegaly is a rare endocrine condition caused by hypersecretion of human growth hormone (GH) that results in elevated circulating levels of GH and insulin-like growth factor-1 (IGF-1). Opko Biologics Ltd. has presented data on the development and characterization of OPKO-8801001, a long-acting human GH receptor (GHR) antagonist with prolonged systemic exposure and pharmacological activity designed for subcutaneous administration. http://www.bioworld.com/articles/732113 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732113-opko-biologics-characterizes-new-compound-for-acromegaly Pipet, test tubes, chemical structures Brightgene Bio-Medical Technology Co. Ltd. has divulged new gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of neurodegeneration, bone, metabolic and cardiovascular disorders. http://www.bioworld.com/articles/732103 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732103-brightgene-bio-medical-technology-synthesizes-new-gipr-gcgr-and-glp-1r-agonists Ethyreal Bio Inc. has developed ETHY-001, a half-life-extended monoclonal antibody targeting thyroid-stimulating hormone receptor (TSHR) designed to prevent the production of pathogenic autoantibodies (TSAbs) to treat Graves’ hyperthyroidism and thyroid eye disease (TED). http://www.bioworld.com/articles/732094 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732094-ethy-001-fully-blocks-tshr-in-graves-preclinical-data Close up of woman's bulging eyes Prime Medicine Inc. has obtained clearance from the New Zealand authority, Medsafe, for the company’s clinical trial application for PM-577a, an investigational Prime Editor for Wilson’s disease. http://www.bioworld.com/articles/732030 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732030-prime-medicines-pm-577a-cleared-for-clinic-for-wilsons-disease Missing puzzle piece and broken DNA chain At the recent Endocrine Society meeting in Chicago, Kalohexis Inc. presented preclinical efficacy data on 710GO, an oral dual MC3R/MC4R agonist, in obese nonhuman primates (NHPs). http://www.bioworld.com/articles/732029 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732029-kalohexis-dual-agonist-achieves-sustained-fat-loss-with-minimal-rebound Constantiam Biosciences Inc. and Cincinnati Children’s have established a strategic collaboration, through an exclusive option for future licensing rights, to advance first-in-class small-molecule treatments for neuronopathic Gaucher disease (types 2 and 3). http://www.bioworld.com/articles/732026 Fri, 19 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732026-constantiam-and-cincinnati-childrens-enter-gaucher-collaboration Researchers from Rivus Pharmaceuticals Inc. presented preclinical efficacy data on RV‑202, a novel oral mitochondrial uncoupler with activity attributed to adenine nucleotide translocase (ANT) activation, in models of obesity. http://www.bioworld.com/articles/732015 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732015-ant-activating-uncoupler-rv-202-drives-selective-fat-loss-in-obese-mice Obesity, fat cell research concept image Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist developed using the company’s proprietary technology platform for the treatment of life-threatening hypoglycemic episodes associated with post-bariatric hypoglycemia (PBH). http://www.bioworld.com/articles/732010 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732010-cftx-2034-successfully-shows-promise-for-post-bariatric-hypoglycemia-in-preclinical-research Illustration of glucose in the blood stream Beam Therapeutics Inc. has obtained IND clearance from the FDA for BEAM-304 for the treatment of phenylketonuria (PKU). BEAM-304 is a liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct mutations in the phenylalanine hydroxylase (PAH) gene that cause PKU. http://www.bioworld.com/articles/732008 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732008-beam-therapeutics-beam-304-gains-ind-clearance-for-pku Chinese peptide therapeutics developer Shaanxi Micot Pharmaceutical Technology Co. Ltd. is seeking up to HK$1.22 billion (US$155 million) in a Hong Kong IPO to advance its lead phase III chronic kidney disease candidate, MT-1013, and next-generation obesity therapies. http://www.bioworld.com/articles/731909 Wed, 17 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731909-chinas-micot-targets-hk12b-ipo-to-advance-metabolic-portfolio IPO, coins, upward arrow